Several large health maintenance organizations have announced that they are dropping out of the Medicare+Choice program, citing inadequate funding and overregulation. Humana Inc., Louisville, KY; Aetna U.S. Healthcare, Hartford, CT; Foundation Health Systems Inc., Woodland Hills, CA; and UnitedHealth Group Inc., Minnetonka, MN, among the largest plans, have announced that, as of Jan. 1, 2001, they will no longer be offering the supplemental insurance in many states and counties. Plan members in those areas will need to switch to higher-cost, traditional fee-for-service Medicare, which lacks a prescription drug benefit.
Several large health maintenance organizations have announced that they are dropping out of the Medicare+Choice program, citing inadequate funding and overregulation. Humana Inc., Louisville, KY; Aetna U.S. Healthcare, Hartford, CT; Foundation Health Systems Inc., Woodland Hills, CA; and UnitedHealth Group Inc., Minnetonka, MN, among the largest plans, have announced that, as of Jan. 1, 2001, they will no longer be offering the supplemental insurance in many states and counties. Plan members in those areas will need to switch to higher-cost, traditional fee-for-service Medicare, which lacks a prescription drug benefit.
According to the American Association of Health Plans, the health plan withdrawals will affect more than 700,000 beneficiaries. "The significant underpayments to and the excessive regulatory burdens on Medicare managed care organizations have forced plans to make the painful decision to withdraw from the market," said Chip Kahn, president of the Health Insurance Association of America. "Most Medicare HMOs would like to continue offering quality healthcare coverage to seniors, but the current situation makes participation financially untenable."
To fix the problem, the health plan industry is calling for regulatory changes, as well as reforms in the way the government administers payments. "This [reform] package should include direct increases in government baseline payments, budget-neutral implementation of the risk-adjuster and steps to insure that counties receive blended payments as envisioned in the Balanced Budget Act of 1997," said Karen Ignagni, president and CEO of the American Association of Health Plans. "These payment changes should be accompanied by meaningful regulatory reform so beneficiaries are assured quality and value in their Medicare+Choice plans." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.